KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbCellera Biologics (ABCL) Revenue (2020 - 2026)

AbCellera Biologics filings provide 7 years of Revenue readings, the most recent being $8.3 million for Q1 2026.

  • Quarterly Revenue rose 96.34% to $8.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $79.2 million through Mar 2026, up 242.66% year-over-year, with the annual reading at $75.1 million for FY2025, 160.56% up from the prior year.
  • Revenue hit $8.3 million in Q1 2026 for AbCellera Biologics, down from $44.9 million in the prior quarter.
  • Across five years, Revenue topped out at $316.6 million in Q1 2022 and bottomed at $4.2 million in Q1 2025.
  • Average Revenue over 5 years is $37.4 million, with a median of $10.0 million recorded in 2024.
  • The largest annual shift saw Revenue soared 1740.65% in 2022 before it crashed 96.15% in 2023.
  • AbCellera Biologics' Revenue stood at $21.5 million in 2022, then crashed by 57.4% to $9.2 million in 2023, then tumbled by 44.98% to $5.0 million in 2024, then surged by 788.18% to $44.9 million in 2025, then plummeted by 81.46% to $8.3 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Revenue are $8.3 million (Q1 2026), $44.9 million (Q4 2025), and $9.0 million (Q3 2025).